呼吸测试读者LumiraDx™ CLIA Waived

Features

• The LumiraDx Platform is an innovative, next generation point of care system that combines a small, portable instrument, advanced low cost test strip and seamless digital connectivity
• Enzyme and immunoassay on a single platform
• Its proprietary technology enables it to deliver exceptional point of care clinical performance, while being simple and easy to use
• Performance referenced to laboratory test
• Portable instrument, seamless connectivit
• One simple, intuitive test workfow
• Fast results in minutes
• All common clinical samples
• Small sample size including capillary blood
• Ability to perform Quality Control Tests using LumiraDx Quality Control to meet regulatory compliance requirements
• 2 x USB ports, RFID reader 13.56 MHz, 0 dBi (EIRP), Bluetooth low-energy 2.4 GHz ISM band, 2400 MHz to 2483.5 MHz, 0.5 dBm (ERP)
• Lithium ion polymer 7.4 V 5000 mAh battery
• High contrast touchscreen with a wide viewing angle
• Uses small sample volumes and multiple convenient sample types, including nasal swab and capillary blood
• Pipeline of 30+ assays, initially focused on some of the most common conditions being diagnosed or managed with POC testing
• The LumiraDx SARS-CoV-2 Ag Test has been authorized by FDA under an EUA only for the detection of SARS-CoV-2 nucleocapsid protein
• The LumiraDx SARS-CoV-2 Ab Test has been authorized by FDA under an EUA only for detecting the presence of total antibodies to SARS-CoV-2